287 related articles for article (PubMed ID: 24704346)
1. Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program.
Nasser F; Cavalcante RN; Galastri FL; de Rezende MB; Felga GG; Travassos FB; De Fina B; Affonso BB
J Vasc Interv Radiol; 2014 Jul; 25(7):1012-7. PubMed ID: 24704346
[TBL] [Abstract][Full Text] [Related]
2. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.
Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS
J Vasc Interv Radiol; 2012 Oct; 23(10):1286-93.e1. PubMed ID: 22999748
[TBL] [Abstract][Full Text] [Related]
3. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
[TBL] [Abstract][Full Text] [Related]
5. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
[TBL] [Abstract][Full Text] [Related]
7. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and nontarget effects of transarterial chemoembolization in bridging of hepatocellular carcinoma patients to liver transplantation: a histopathologic study.
Stampfl U; Bermejo JL; Sommer CM; Hoffmann K; Weiss KH; Schirmacher P; Schemmer P; Kauczor HU; Richter GM; Radeleff BA; Longerich T
J Vasc Interv Radiol; 2014 Jul; 25(7):1018-1026.e4. PubMed ID: 24768235
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles.
Padia SA; Shivaram G; Bastawrous S; Bhargava P; Vo NJ; Vaidya S; Valji K; Harris WP; Hippe DS; Kogut MJ
J Vasc Interv Radiol; 2013 Mar; 24(3):301-6. PubMed ID: 23380737
[TBL] [Abstract][Full Text] [Related]
10. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization with drug-eluting beads is effective for the maintenance of the Milan-in status in patients with a small hepatocellular carcinoma.
Manini MA; Sangiovanni A; Martinetti L; Viganò D; La Mura V; Aghemo A; Iavarone M; Crespi S; Nicolini A; Colombo M
Liver Transpl; 2015 Oct; 21(10):1259-69. PubMed ID: 26074360
[TBL] [Abstract][Full Text] [Related]
13. Response Evaluation Criteria in Solid Tumors (RECIST) criteria are superior to European Association for Study of the Liver (EASL) criteria at 1 month follow-up for predicting long-term survival in patients treated with transarterial chemoembolization before liver transplantation for hepatocellular cancer.
Shuster A; Huynh TJ; Rajan DK; Marquez MA; Grant DR; Huynh DC; Jaskolka JD
J Vasc Interv Radiol; 2013 Jun; 24(6):805-12. PubMed ID: 23562641
[TBL] [Abstract][Full Text] [Related]
14. Modified cisplatin-based transcatheter arterial chemoembolization for large hepatocellular carcinoma: multivariate analysis of predictive factors for tumor response and survival in a 163-patient cohort.
Yoon HM; Kim JH; Kim EJ; Gwon DI; Ko GY; Ko HK
J Vasc Interv Radiol; 2013 Nov; 24(11):1639-46. PubMed ID: 23962438
[TBL] [Abstract][Full Text] [Related]
15. Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile.
Odisio BC; Ashton A; Yan Y; Wei W; Kaseb A; Wallace MJ; Vauthey JN; Gupta S; Tam AL
J Vasc Interv Radiol; 2015 Jul; 26(7):965-71. PubMed ID: 25979305
[TBL] [Abstract][Full Text] [Related]
16. Outpatient Transarterial Chemoembolization of Hepatocellular Carcinoma: Review of a Same-Day Discharge Strategy.
Fritsche MR; Watchmaker JM; Lipnik AJ; Baker JC; Geevarghese S; Banovac F; Omary RA; Brown DB
J Vasc Interv Radiol; 2018 Apr; 29(4):550-555. PubMed ID: 29478795
[TBL] [Abstract][Full Text] [Related]
17. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
Sacco R; Bargellini I; Bertini M; Bozzi E; Romano A; Petruzzi P; Tumino E; Ginanni B; Federici G; Cioni R; Metrangolo S; Bertoni M; Bresci G; Parisi G; Altomare E; Capria A; Bartolozzi C
J Vasc Interv Radiol; 2011 Nov; 22(11):1545-52. PubMed ID: 21849247
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of 70-150 μm and 100-300 μm drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
Deipolyi AR; Oklu R; Al-Ansari S; Zhu AX; Goyal L; Ganguli S
J Vasc Interv Radiol; 2015 Apr; 26(4):516-22. PubMed ID: 25704226
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation.
Chapman WC; Majella Doyle MB; Stuart JE; Vachharajani N; Crippin JS; Anderson CD; Lowell JA; Shenoy S; Darcy MD; Brown DB
Ann Surg; 2008 Oct; 248(4):617-25. PubMed ID: 18936575
[TBL] [Abstract][Full Text] [Related]
20. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors.
Chern MC; Chuang VP; Liang CT; Lin ZH; Kuo TM
J Vasc Interv Radiol; 2014 Jan; 25(1):32-40. PubMed ID: 24290099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
